Review Article

Integration of botanicals in contemporary medicine: road blocks, checkpoints and go-ahead signals

Neha Arora Chugh, Shreya Bali, Ashwani Koul*

Department of Biophysics, Panjab University, Chandigarh, India

ARTICLE INFO

Article history:
Received 22 September 2017
Revised 7 March 2018
Accepted 22 March 2018

Keywords:
Botanicals
Complementary and alternative medicine
Contemporary medicine

ABSTRACT

The use of botanicals for maintaining good health and preventing diseases is undisputed. The claimed health benefits of natural health products and herbal medicines are based on traditional claims, positive results obtained in preclinical studies and early phase clinical trials that are not backed by safety and efficacy evidences approved by regulatory agencies. Although, the popularity of botanicals is growing, health care practitioners of modern medicine seldom recommend their use because of ill equipped database of their safety and potency. This review discusses problems that preclude botanicals from integrating into the mainstream contemporary therapeutics and cues that provide impetus for their realisation.

© 2018 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The use of plants for therapeutic purposes can be traced back to the Neanderthal period and since then their use for remedial purposes has been growing.1 Animals have also been consuming plants for their healing properties and such serendipitous occurrences have provided leads for identifying plants with medicinal potentials.2-5 Many of the drugs in modern therapeutics are natural products or have been derived from them (plants, microbes, marine organisms/plants, insects, animals).6-9 Data collected over the years from drug manufacturing community has indicated that about 50% of drugs available in the last several decades had natural origin and around 27 anticancer drugs including actinomycin D, paclitaxel, vincristine, topotecan, dexamethasone, etoposide, tamoxifen etc. developed during the period 1940–2010, were from natural sources.8-10

The search for medicinally relevant compounds from natural sources is relatively easy because they have a history of use in prevention and/or treatment of diseases. Thus, drug discovery from herbal sources is experience driven and on the contrary, the search of a clinically useful compound ‘de novo’ with no source leads is a ‘shot in the dark’. Drug development from plants is carried out in three elaborate steps namely: pre-drug stage; quasi drug stage and full drug stage.11 Pre-drug stage
is the first stage of drug development and involves the information driven selection of herbs or plants, based on results obtained in animal studies, experience obtained by their indigenous use and through self-medication. Thus, fruits, vegetables, spices, and traditional medicinal plants are obvious targets for this approach. Once cleared through the pre-drug stage, the plant enters the quasi drug stage which involves the preparation of extracts, screening of phytochemicals, structure and composition elucidation, bioactivity evaluation and identification of possible lead compounds using modern techniques. Once the lead compound is identified, it is structurally modified if needed. It is then evaluated in animal models, in-vitro studies and clinical trials and upon approval, it enters as a marketed drug. All these comprise the full drug stage. Although, modern, scientific and high through put technologies are available for the drug discovery process, however, unless these take care of the ADME/Tox profile (i.e., absorption, distribution, metabolism, excretion, and toxicity) they may not be able to successfully produce a good medicinal product.

The drug development process is growing at an enormous pace and it is undeniable that chemically synthesized drugs have revolutionised the field of medicine. Despite, the well established system of modern conventional medicine, plants still continue to provide benefits for medicinal purposes to about 80% of the world population, largely in developing countries. Over 70–95% of the population in Africa, Asia, Latin America and Middle East use some form of traditional medicine as their first line of treatment. Majority of the hospitals in China have well established units rendering treatment through traditional healing systems. In China, traditional Chinese medicine (TCM) was very widely used for controlling severe acute respiratory distress syndrome and in Africa, traditional herbal medicine was used to alleviate symptoms associated with human immune deficiency virus (HIV) infection. Plant based remedies are the primary form of healthcare amongst the underprivileged sections of populations because of poverty and limited access to modern medicine.

Complementary and alternative medicine (CAM) therapies is divided into two broad categories namely drug based CAM therapies and non-drug based CAM therapies. Plants constitute about 80% of the drug based CAM therapies. There has been a change of perception among the general public and adoption of alternative remedies has increased even in the developed nations. Particularly, herbal medicine is drawing attention and has given a boost to the pharmaceutical market in international trade. Global giants in pharmaceutical manufacturing have been aggressively investing in herbal medicine. Chinese herbal medicine registered an increase of 20 percent in sales in 2012 from the previous year, reaching to about US$83 billion. The international market for herbal supplements and remedies is expected to reach US$115 billion by 2020, with Europe being the largest and Asia-Pacific being the fastest growing market. Worldwide, about 35,000 plant species are being used for medicinal purposes. The Indian herbal industry uses about 960 plant species and among these about 178 have huge consumption surpassing hundred metric tonnes. Among the European countries, Germany and France have the largest sales of herbal medicines. The use of herbal supplements is also very popular in United States of America (USA) and their eminence for purported health benefits is on a continuous rise.

Modern medicine targets the disease usually by employing a single agent (monotherapy). Traditional healing systems like ayurveda employ different approaches like medicinal herbs, yoga, dietary control, meditation, prayers etc for restoring balance in the body and alleviation of diseases. Traditional systems of medicine are based on the holistic treatment of the patient which also takes into consideration behavioral, physiological, psychological effects of drugs on the mind-body complex. Ayurvedic medicinal preparations contain combination of medicinal plants, minerals, metals etc. Polyherbal formulations are recommended as they provide synergism of positive effects and antagonism of negative effects and drug associated side effects. The use of multiple herbs in combination with other ingredients and modalities serves well to provide symptomatic relief alongside targeting the disease at the tissue level. The modern chemotherapeutic approaches which are largely ‘molecule driven’ have taken an edge over traditional healing systems because plant based preparations and other complementary modalities are slow to act and provide relief gradually, in comparison to the drugs used in modern medicine. However, the ill effects emanating from the use of these drugs has provided grounds for renewed interest in traditional therapies.

The increase in adoption of herbal remedies may be ascribed to: a general preference of natural therapies and aversion for other interventions like surgery, allopathic medicines etc; inclination towards self-medication based upon experience; affordable cost of herbal medicines and ease of availability; side effects associated with conventional medicines (especially in cases of chronic problems) and growing promotion of herbal medicines. Herbal remedies are generally used and/or recommended for maintaining good health, alleviation of chronic problems and rarely for acute and/or life-threatening problems. People begin using alternative forms of treatment, including herbal medicine when conventional medicine is ineffective or for pain palliation in case of long standing problems like cancer, arthritis etc. The use of natural dietary supplements among the general population is also very popular in an attempt to prevent cancer. The use of dietary supplements (containing natural products) among cancer patients in USA has become very popular and many patients begin using new dietary supplements with natural ingredients after being given a cancer diagnosis. Botanicals when sold commercially are often referred to as ‘natural health products (NHPs) or herbal medicinal products (HMPs)’. They are available as single isolated/enriched compounds or as complex mixtures of several biologically active compounds and they may be obtained from single herb or combination of herbs (polyherb formulations). They are prepared in a variety of ways and can be taken in the form of decoction, tinctures, essential oils, teas, syrup, ointments, salves, and tablets/capsules that contain powered form of the whole plant/plant part or dried extract.

Although, the adoption of herbal medicine/botanicals in preventing and/or curing diseases through self-medication instigated by promotion in popular media has seen a surge, however, its acceptance among health care practitioners is not very encouraging. Strange as it may appear, but many
professional health practitioners admitted to having little knowledge regarding herb supplements, which discourages their prospective clinical trials and use. It was revealed in a survey that oncologists did not have enough knowledge about the use of herbs and dietary supplements and did not receive any training in this regard. Due to lack of concrete evidence and scientifically robust studies evaluating their potential risks and benefits, oncologists find it challenging to give advice to patients regarding their use, probable positive or negative impact along with the use of other treatment modalities like radiotherapy, chemotherapy, hormonal therapy, immunotherapy etc.\(^7\),\(^2\)

Although, many botanicals are in the pipeline of clinical trials however, they have met with little success because of the study limitations.\(^4\) Therefore, health care practitioners seldom recommend/prescribe their use in ailments. The widespread promotion of the natural products/dietary supplements claiming their health benefits through television, internet etc is one of the major sources through which the consumers gain knowledge about these products. These claims are usually not backed by any regulatory authority and generally are based on positive results obtained in pre-clinical investigations in animal models, cell lines and/or small early phase clinical trials. The use of these products bereft of any safety and efficacy studies is likely to have some detrimental effects. For instance, in USA, for cancer, several clinical trials have been conceived and initiated but Food and Drug Administration (FDA) has not approved any phytoproduct in cancer therapy. A lot of natural dietary supplements have undergone phase 2 trials; however, majority failed to follow the up phase 3 trials.\(^3\),\(^7\) Plant extracts encounter steep failure rates in clinical trials which is in sharp contrast to the enormous benefits they exhibit in pre-clinical studies.\(^3\) Thus, they fail to obtain the regulatory approval as potential treatment options.

This review discusses various problems encountered with botanicals/phytomedicine and its possible integration with the contemporary medicine (Fig. 1). Some of the impediments are inherent to this healing system and there are other problems which fall in the ambit of regulations and procedures. Even though, there has been a paradigm shift in the mindset of people regarding the use of natural products, however unless backed by their safety and efficacy proofs they are unlikely to be recommended as popularly as the contemporary form of medicine.

2. Problems that keep botanicals away from being included in the mainstream alternatives for health promotion and disease management

Scientifically sound and robust procedures and guidelines have been laid down for assessing safety, efficacy, pharmacokinetics, quality, good manufacturing practices (GMP), post marketing surveillance etc of conventional putative drugs. However, such rigorous procedures are lacking for herbal products. In addition, clinical trials with herbal products are associated with poor design and reporting. This is surprising considering the fact that this form of medicine enjoys such tremendous popularity amongst the people of both developed and developing nations and of all cultures and religion. All these reasons account for the hazy reputation of botanicals.

2.1. Challenges of clinical trials: impediments in trial designing, poor design of trials and their reporting, economically unviable trials

Carrying out of randomised, placebo-controlled trials is essential in the evaluation of any drug for health benefits or disease mitigation.\(^3\) Usually herbal medicines have a peculiar color, taste and smell which make it difficult to carry out placebo-controlled trials.\(^4\),\(^4\) In addition, the decision to choose an ‘active reference medicine/comparator’ as a herbal product or one that from modern medicine is an area of concern. Quite literally, it is very difficult and impractical to have active and control groups with similar organoleptic features when using herbal products.\(^4\) The differences in the type of formulations used, although containing the same ingredients yield different results owing to the varying bioavailability of the active constituents.\(^5\) Although, the inclusion and exclusion criteria for enrolling patients in clinical trials with HMPs could be based either on modern or traditional practice, however, confounding situations could arise if the disease criteria vary in both the systems.\(^6\) The inclusion and exclusion criteria for trials with herbal medicine are challenged by the non-uniformity in medical systems across countries.\(^4\) Overlooking such issues can allow for faulty interpretations and conclusions. For instance, the criteria for patient selection by American researchers for testing the potential of a herb on heart failure would be based on the disease features recognized by the New York Heart Association, which drastically differs from the ‘yin and yang’ perspective of disease development by the practitioners of TCM.\(^1\)

Ayurveda (Indian form of traditional herbal medicine) treats patients on the basis of ‘prakriti’ or the ‘psychosomatic’ constitution. This is an individualistic thing and Ayurveda recommends compounding/mixing of herbs, dosage and duration for an individual. Therefore, the effect of one particular treatment regimen of an ayurvedic remedy would be inappropriate to generalise to a subject population with varying psychosomatic constitution in clinical studies.\(^4\),\(^5\) Such generalisation could also be difficult to apply to other traditional forms of medicine like TCM which lays stress on personalised medicine.\(^5\)

Clinical evaluation of herbal drugs has been found to have shortcomings in trial design, improper execution and weak data analysis.\(^5\) Inappropriate number of patients in trials, improper randomisation and selection bias has been observed in previous clinical trials with herbal medicines.\(^5\),\(^5\) Enrolling fewer participants in the trial make it difficult to reach to a statistically significant conclusion. Many a times, doubts and objections have been raised on the methodology and inferences drawn from clinical trials of herbal treatments. In addition, reports on herbal drugs are incomplete with respect to the recommendations of Consolidated Standards of Reporting Trials (CONSORT) guidelines,\(^5\)\(^5\) explaining the elusiveness and contradiction in their safety and efficacy reviews.\(^5\),\(^6\) Considering these limitations, Cochrane reviews had concluded that with herbal drugs no well-designed trial has been conducted and that there is not enough supporting
Fig. 1 – Inclusion of botanicals in contemporary medicine: obstacles encountered and potential solutions (a brief summary)

Evidence for their safety and effectiveness for the proposed clinical condition. Poor quality of trials and their reporting give way to under or overestimation of the treatment effects which are bound to have undesired effects. Also, the conclusions made regarding the efficacy are surrounded by doubts linked to poor quality of reporting and poor design and conduct of trials. Very few clinical trials involving traditional herbal medicines in Africa and China have been reported to be of adequate quality and problems have been recognised with regard to number of patients recruited, placebo preparation etc.

Repetitive and large scale clinical trials are complicated, time consuming and expensive procedures. Usually, the compound/drug molecule undergoing clinical trials is patented by the pharmaceutical company and these are then sold at a premium providing opportunities for the manufacturers to gain profits. Usually, manufactures of food products, herbal products etc are not given patent protection and therefore face price competition. Limited profits incurred dissuade them from paying the hefty costs involved in large phase 3 trials. In USA, since FDA approval is not mandatory for selling dietary supplements containing herbal ingredients, therefore,
manufactures avoid going through randomised, placebo-controlled phase 3 trials and continue promoting their products based upon the positive results obtained in phase 2 trials. Due to the fact that plants cannot be patented, therefore drug manufacturers see fewer opportunities for huge profit making. In USA, approximately $5.5 billion to 5.9 billion and 15 years is the amount of money and time spent in bringing a new drug to the market.\textsuperscript{2,73} Without huge profits in sight, very few companies are willing to invest in satisfying FDA requirements.

2.2. Problems of complexity: difficult pharmacokinetic evaluation and dosage calculation

Pharmacokinetic studies are difficult to carry out on polychemical natural products.\textsuperscript{74} This is because many a times, the active ingredient/active principle is not known, and also the presence of several different active components make the pharmacokinetic evaluation difficult and complex.\textsuperscript{75–77} The problems of pharmacokinetic profiling in phase I of drug development are further compounded in cases when polyherbal formulations are used. This requires standardisation of several active compounds and their estimation in the body fluids.\textsuperscript{78} Pharmacokinetic evaluation becomes very elaborate when patients simultaneously seek treatment from traditional and contemporary medicine systems.

Pharmacokinetic herb–drug interactions are mediated by modulations in cytochrome P450s (CYPs) and drug transporters (P-glycoprotein).\textsuperscript{79} CYPs are primarily involved in drug metabolism and are abundantly present in liver and small intestine. CYP3A4, one of the isofoms of CYPs is an important drug metabolising enzyme (DMEs) that is involved in the herb–drug interactions.\textsuperscript{80} It is responsible for oxidising about 60% of drugs to less active or readily excretable metabolites and its level of activity determines the bioavailability of the drug. Any alteration in the activity of CYP3A4 gets reflected in the bioavailability of drugs that are oxidised by this CYP. For instance, it has been observed that grapefruit reduces enteric CYP3A4 activity, thereby elevating the levels of some drugs to toxic levels.\textsuperscript{81} On the contrary, St John’s wort, which is used in the treatment of depression increases CYP3A4 activity and P-glycoprotein, consequentially leading to diminished clinical response of drugs like cyclosporine and indinivir.\textsuperscript{82,83} Since, the drug entities of both the systems are metabolised by the same monooxygenase system (DMEs) in the body, therefore pharmacokinetic interactions are inevitable. Further, polymorphism in DMEs is likely to have its own influence on the way individuals respond to herbal medicines.\textsuperscript{84}

Conventional medicines are carefully studied for their dose effect response and accordingly safest dose is calculated taking into consideration body weight, drug interactions etc and possibly minimising the scope for negative effects.\textsuperscript{44,85,86} Dose calculation is a tricky area to resolve in herbal medicine due to several reasons. Very often the active ingredient/s and the quantity is unknown in the herb and its raw material by which the herbal medicine is prepared. More so, very rarely it is known as to how the levels of the active constituents vary with the kind of processing the herb undergoes for preparation of drug.\textsuperscript{87} In vitro and pre-clinical studies involve prolonged exposure to high concentrations of the phytoproduct. This may be difficult to imitate in humans because of limited oral bioavailability, known and unknown adverse effects and drug interactions rendering such treatment regimens unsuitable.\textsuperscript{88} Because of the inadequate studies determining the interactions of herbal medicines with the conventional medicines there is a likelihood of adverse drug reactions (ADRs). Not only this, insufficient information is available regarding the dose dependent effects and possible side effects of the same on consumption of higher doses. For instance, although herbal remedies are effective in controlling progression of liver diseases, however some of the compounds present in these medicines can have deleterious effects. Thus, this necessitates careful dose escalation and efficacy testing which involves complex pharmacokinetic and dose calculation studies.\textsuperscript{89} Traditional forms of medicine used in China, Japan, Korea, India etc are mainly used in the form of decoction which involves boiling of the plant parts to extract/enrich the compounds of interest. Decocations suffer from disadvantages like dosage quantification, composition stability, quality control etc. Discrepancies in the reported dosage and treatment duration of herbal remedies; poor standardisation and lack of quality control of herbal preparations, presence of several active compounds are some issues that make the dose calculation tedious.\textsuperscript{77}

2.3. Product categorization affects safety assessments: pre-marketing and post-marketing safety checks

Herbal products are classified and regulated depending upon countries/jurisdiction.\textsuperscript{90} The regulatory requirements for products labelled as ‘food’ are less stringent than those labelled as ‘drugs’ or ‘medicinal products’. This categorisation varies between countries and sometimes even within the countries.\textsuperscript{91,92} Product categorisation can be a difficult task, sometimes vague, presenting challenges to the regulatory authorities. The claims made regarding the products entils them either into food or drugs i.e. products which claim no health or medicinal benefits (treat or prevent diseases) are labelled as ‘food’. For instance, if products containing garlic are claimed to exhibit health benefits then they are regulated as drugs, else are sold as food.\textsuperscript{88}

In USA, herbal products are classified as dietary supplements or special foods and since they are not considered as drugs, therefore they can be sold without clinical trials and do not require pharmacovigilance reporting.\textsuperscript{93} Thus, FDA does not subject them to the same strict and thorough intensity checks of proof and safety. They are regulated under the Dietary Supplement Health and Education Act, which allows their use without having them to clear the strict quality control tests of Drugs and Cosmetics Acts (1994). FDA only reviews these products and does not approve them. Accordingly, it is not mandatory for manufacturers to test them in clinical trials before marketing them, thus allowing for any untoward effects that could occur with their use. FDA can disallow a company from making a supplement after it has been shown to cause adverse effects.\textsuperscript{94} Several such cases have been reported where herbal products have been recalled after they were found containing banned substances or substances unfit for consumption like prescription drugs etc. FDA banned the sale of ephedra following reports of ephedra-related toxicity and deaths.\textsuperscript{95} This is in striking contrast to the regulations for
prescription and non-prescription drugs which are required to be proven safe before selling. Pharmacovigilance reporting (ADR reporting) is also not mandatory for manufacturers of herbal dietary supplements.96 In the European Union (EU), herbal products are classified either as herbal medicines or as food supplements depending upon the claims made. Herbal medicines in EU are required to satisfy safety and quality standards but food supplements are not required to do so. Complexity arises in cases when the same herb or mixture of herbs is being supplied as herbal medicine and dietary supplement. Thus, labelling a herbal product as drug or food has implications in its pre-marketing (quality control, clinical trials) and post marketing safety checks (pharmacovigilance).96 In China, natural products are considered as medicinal products and therefore are subjected to similar level of regulatory control as for the conventional medicines. The regulatory guidelines for countries like Canada, Singapore, Australia etc vary and regulate the products accordingly.68 This non-uniformity in product categorisation not only affects their pre-market and post-market control, their safety and efficacy, but also poses challenges in trans-national movement of products.

2.4. Challenges of pharmacovigilance: complexity of nomenclature and consumer related issues

Since herbal drugs available worldwide come from China, India, Brazil, Africa, several countries of Europe, South America etc, therefore there are problems that come up due to diversity. This brings to the forefront questions such as what should be the appropriate naming system (Latin, pharmaceutical, generic, herbal drug name) and accurate validation of the constituent herbs. Plants/herbs are generally known via their Latin scientific name, vernacular name, pharmaceutical name or pharmacopoeial name or specific herbal drug names (as used in TCM or Indian herbal medicine). Sometimes, different herbal ingredients are known by a single name allowing for misidentification and inadvertent use of herbal products leading to undesired effects.68 The roots of Aristolochia fangchi, Stephania tetrandra and Cocculus trilobus are commonly known as Fang ji. A. fangchi (Guang Fang ji) was mistakenly consumed instead of S. tetrandra (Han Fang ji) for its weight loss benefits and consumers reported severe renal problems. Upon careful analysis it was found that inadvertent consumption of aristolochic acid containing A. fangchi (Guang Fang ji) products was responsible for such adverse effects.97–99 This was followed by a ban of aristolochic acid containing herbal products in EU, USA and Australia. However, misidentification of herbs due to confusion/similarity in common names continued the production and consumption of aristolochic acid containing herbal products.100–104 Product labelling of drugs may use one or more of these naming systems and at times the drugs are even sold without any labels. The non-uniformity in describing herbal constituents makes ADR and analysis confounding, sometimes wrongly implicating a herb to the observed negative outcomes. Although, common names are frequently used in USA and EU for the purpose of reference, however, EU regulatory authorities recommend the use of Latin scientific names.96 Reporting of herbal ADRs is of use only if the reporter is aware of what herb/product was used. This requires correct identification of the plant/herb by the user. Inadequate or inappropriate use of names can cause confusion. For instance, ADRs reporting by referring to the use of ‘ginseng’ could point out to a variety of plants, their species or even unrelated plants. ‘Ginseng’ may refer to Panax ginseng C.A. Mey or Panax quinquefolius (Burk.) F.H. Chen or other plants that are also referred to as ginseng such as Eleutherococcus senticosus (Rupr. & Maxim) Maxim (Siberian ginseng) or the unrelated Withania somnifera (L.) Dunal (Indian Ginseng).96

It is a general perception among consumers that herbal products have low risk so much so that anything natural is synonymous with being safe. Any untoward effects observed upon their consumption are generally not accepted and thus ‘cause–effect’ is not acknowledged in this case. Because of this unawareness or paucity of information, users very often defer the notion that their adoption of herbal remedy may be causing the observed unfavourable effects. Thus, their prolonged use of herbal products could aggravate the problem. This is particularly prevalent in the developing countries where use of traditional herbal medicine is very popular and the system of reporting ADRs is not well constituted. Surveys conducted in developed nations like USA, Canada, United Kingdom (UK), Australia have indicated that in these nations ‘passive surveillance’ (voluntary spontaneous reporting) is the prime source of gathering information about adverse effects emanating from the use of medicinal products including NHPs.105 Although, passive surveillance has the advantage of revealing adverse effects in ‘real’ situations (large population/wide consumer base) however, it has its limitations which can be understood from the fact that since this system depends upon voluntary reporting by the practitioners and/or patients, less than 1% of adverse effects are reported.106 More so, patients and health care practitioners are less likely to report adverse effects associated with the use of NHPs than with the conventional over the counter medications. It has also been observed that physicians do not routinely inquire patients about use of NHPs.106–111 Collectively, all these factors contribute to the inadequacy of the passive surveillance to identify NHP associated harms. Active surveillance which involves keeping track of adverse events using a carefully chalked out pre-organized process are well established for conventional prescription medicines but its application to NHPs is limited till date.112–114 For reasons known and unknown, patients do not divulge to their clinicians about their use of herbal medicines.38 The consumers are unaware of the importance of reporting the use of herbal products or the adverse effects that may have emanated from their use.115 In case of ill effects, patients and health care professionals can report such events, but such reporting is not mandatory.94 This leads to underreporting of their adverse effects which contributes to their poor database of toxicity and drug interactions.

2.5. Adverse reactions: an outcome of poor quality control, herb–drug/herb–herb interactions

Several reports are available regarding the undesirable effects of natural products, sometimes with very dire consequences. Such observations have been reported amongst the users of both developed and developing nations. The adverse effects emanating from the use of herbal products can be attributed
to the toxic effects of the inherent constituents or the adulterants/contaminants that are present in the preparation and also herb–drug/herb–herb interactions. Owing to the poor quality control standards and improper regulation of purity and potency, herbal products fall short in comparison to the conventional drugs. Poor quality control systems and lack of stringent monitoring systems lead to the contamination/adulterations of herbal preparations.

Herbs obtained from polluted sites (areas with soil, water or air pollution due industrial emissions) or poor farming practices lead to the production of low quality products unfit for human consumption.\textsuperscript{116,117} Herbal preparations although prepared from same herbs each time may vary from batch to batch because the phytochemical content could fluctuate depending upon the harvesting time of the plant, climatic conditions, geographical locations, harvesting methods and environmental conditions could affect the presence of certain elements (like heavy metals) depending upon the conditions of water, soil and air in that region.\textsuperscript{32,86,118} Inappropriate storage conditions can affect the quality of herbal products if they get subjected to fungal or bacterial contamination and also excessive drying can lead to loss of thermo-labile bioactive constituents.\textsuperscript{84,86} Variations may also arise in preparations such as extracts, decoctions etc between batches and amongst manufacturers because of the variation in solvents, temperature, extraction time etc.\textsuperscript{17} The variability in the preparation of the herbal products has implications in the health benefits observed.\textsuperscript{67,86} The likely presence of allergens, pollens, toxins (aflatoxin, mycotoxins brevetoxin B, yessotoxins, pecteno-toxins, digoxin, sikimitoxin),\textsuperscript{119-122} microbes (Escherichia coli, Salmonella, Listeria monocytogenes) and heavy toxic metals (mercury, cadmium, lead, arsenic)\textsuperscript{123-128} could be contributing to the observed adverse effects. Several cases of deliberate addition of prescription drugs/other pharmaceutical products (aminopyrine, phenylbutazone, phenacetin, dexamethasone, indometacin, diazepam, hydrocortisone, fluorocinolone acetoneide, diclofenac, mefenamic acid, clobenosol propionate, phenytoin, methylsalyclate, prednisolone, indomethacin and glibencamamide etc)\textsuperscript{123,124,125} in herbal products have come to light. Cadmium, arsenic and lead have been detected in the herbal products with levels exceeding the maximum permissible limits allowed by World Health Organisation (WHO).\textsuperscript{130,131} Inadvertent adulteration and substitution of herbal drugs with incorrect plants/herbs due to confusion in vernacular names, similarity in color and morphology etc is one of the reasons for herbal products exhibiting undesired effects and being unfit for consumption.\textsuperscript{132,133}

Botanicals contain many pharmacologically active compounds that exhibit biological effects in synergism or antagonism. The presence of multiple compounds increases the likelihood of interactions and it is considered that herb–drug interactions could be more pronounced than drug–drug interactions. These interactions could either serve to enhance or diminish the pharmacological or toxicological effects. Such interactions are mediated due to the pharmacokinetic interference of one xenobiotic on another xenobiotic, including metabolism, elimination, absorption etc. All these events would modulate the dose response observed and therapeutic or toxic effects.\textsuperscript{128} Although, interactions could be positive, negative or neutral\textsuperscript{134}, however, they could be of concern if they act to cause damage. Many a times, there is mislabelling/incomplete information provided on the labels which increases the chances of herb–drug/herb–herb interactions etc.\textsuperscript{135-137}

Consumption of poor quality and adulterated products has led to many unfavourable effects ranging from mild to moderate to severe; such as allergic reactions, respiratory complaints, pain, nausea, fatigue, gastrointestinal upset, mood disturbances, muscle weakness, vomiting, confusion, lethargy, seizures, sensory disturbances, compression fractures, leucopoenia, convulsions, persistent hypoglycaemia, Cushing’s syndrome, burns, dermatitis, meningitis, multi-organ failure, arsenic, lead or mercury poisoning, malignancies, hepatic and renal toxicity, cerebral edema, coma, intracerebral haemorrhage, and even death.\textsuperscript{13,129,138}

2.6. Discouraging reimbursement options

Worldwide, the use of CAM is increasing and has been a major contributor to non-reimbursed medical or health expenditure. Insurance companies refuse to cover CAM because they do not completely believe the claims made by the proponents of CAM.\textsuperscript{139} The decision makers in the insurance sector reason out that in the current scenario of escalating healthcare costs, and the constant emergence of new medical technologies and drugs has made them wary of expanding the health care coverage options. They are of the opinion that coverage should only be provided for health facilities that are backed by a robust body of evidence for their safety and effectiveness. Moreover, the lack of information on the use, cost and overall cost-effectiveness of CAM makes it difficult for the insurance companies to respond to the consumer needs and hinders their ability to plan and execute policies related to CAM reimbursement.\textsuperscript{139} In USA, the private insurance companies provide cover to varying degrees for the medical expenses incurred from the accepted standard of care modalities and reimbursement is usually not available for CAM and therefore must be paid of pocket by the consumers.\textsuperscript{140} Although, CAM is very popularly used in UK, however it is not covered by the healthcare system.\textsuperscript{141} Since, the introduction of Statutory Health Insurance Modernization Act in 2004, the sale of herbal medicines has dropped in Germany because of the exclusion of phytotherapeutics from reimbursement.\textsuperscript{142} In USA, Medicare and Medicaid plans selectively provide cover for chiropractic care, massage and acupuncture and have excluded other forms of CAM including phytomedicine from the reimbursement plans.\textsuperscript{143-146} Private insurance companies have begun to include some forms of CAM however pre-authorization, network restrictions, deductibles, co-payments may be more than those laid out for conventional treatment options. Additionally, the number of visits to the clinic/centre and the extent of reimbursement may vary and be limited. In EU, the reimbursement systems and policies differ between the countries and in many countries, CAM is not included in the national health supervision system.\textsuperscript{146} This implies that patients seeking CAM treatment outside of their home country may not be able to receive reimbursement because the CAM reimbursement policies may differ between their country of affiliation and the country of treatment.
Table 1 – Medicinal effects exhibited by some plants

| Plant | Beneficial effects observed | Reported literature |
|-------|----------------------------|---------------------|
| Azadirachta indica (Neem) | Anti-cancer, anti-toxic, anti-viral | 148–154, 156, 175 |
| Lycopersicum esculentum (Tomato) | Anticancer, anti-toxic | 155, 157 |
| Aloe barbadensis (Aloe vera) | Radioprotective | 158, 159 |
| Withania somnifera (Ashwagandha) | Anti-cancer, anti-toxic | 160, 161–164 |
| Ginkgo biloba (Ginkgo) | Neuroprotective, nootropic | 165–168 |
| Alpinia galangal (Greater galangal) | Fertility | 121, 171 |
| Punica granatum (Pomegranate) | Fertility | 121, 171 |
| Viscum album (Mistletoe) | Immunity booster in cancer patients, mitigates chemotherapy associated side effects | 172 |
| Thymus vulgaris (Thyme) | Cold, cough, bronchitis, respiratory tract ailments | 173 |
| Pimpinella anisum (Aniseed) | Cold, cough, bronchitis, respiratory tract ailments | 173 |
| Althea officinalis (Marshmallow) | Cold, cough, bronchitis, respiratory tract ailments | 173 |
| Serenoa repens (Saw palmetto) | Urinary tract ailments | 174 |
| Artemisia annua (Sweet wormwood) | Anti-arthritis, anti-inflammatory | 176 |

3. Growing prospects of botanicals

Although there are numerous deterrents in the field of phytomedicine, however, efforts are being concerted globally to gain maximum benefit from the healing powers of plants. Despite the apprehended hiccups, researchers worldwide have been carrying out pre-clinical studies and clinical trials with botanicals. Agencies like National Institute of Health (clinicaltrials.gov), USA; European Medicines Agency [EMA] (clinicaltrialsregister.eu), London; Indian Council of Medical Research (cri.nic.in), India; National Health and Medical Research Council, Australia (anzctr.org.au) etc in assistance with several government and private institutes undertake clinical trials and maintain their database. Typical pharmacopoeial standards are difficult to apply to herbal medicines and thus require broader and flexible approach in addressing the problem of standardization.85,147 Systems and procedures are being developed and revised to improve quality control, safety and efficacy testing and pharmacovigilance.

3.1. Gathering scientific evidence for their proof of function: pre-clinical and clinical studies

Plants are being continually explored for their medicinal properties in various animal, in-vitro models of diseases and their suitability is also assessed in clinical studies (Table 1). The underlying mechanisms behind the observed beneficial effects are also being studied extensively. Several studies from our laboratory and those of others have demonstrated the anticancer effects of Azadirachta indica (Neem) extract against cancer of various sites in mice.148-154 Lycopene enriched tomato extract has proved beneficial against liver cancer in mice.155 The anticancer activity has been ascribed to their ability to modulate key signalling pathways like cell proliferation, apoptosis, carcinogen biotransformation, DNA repair, immunomodulation etc. Neem and tomato extracts have been effective in ameliorating doxorubicin induced cardiac and renal157 toxicity in mice. Administration of Aloe vera extract provided protection against radiation induced testicular damage in mice by its ability to scavenge free radicals and strengthen the cellular anti-oxidant defense system.158,159 Withania somnifera has the ability to mitigate arsenic induced toxicity in rats.160 Several researchers have investigated the anticancer effects of Withania somnifera against skin, prostate, colon, leukemia etc in animal models and cell lines.161-164 Extracts of Ginkgo biloba has neuroprotective effects as revealed by its ability to prevent ischemic brain damage in mice165 and trimethyltin neuronal toxicity.166 Ginko biloba has also exhibited nootropic effects.167,168 Myriad number of phytochemicals present in fruits, vegetables, herbs etc have been demonstrated to have a wide range of biological activities that are responsible for their medicinal properties.169,170

In a randomised control, double blinded trial, plant extracts of Alpinia galanga (greater galangal) and Punica granatum (pomegranate) were assessed for their effects in improving semen quality in males (NCT01357044; clinicaltrials.gov) and the study findings suggested that subfertile men can gain an improved amount of motile ejaculated sperms by taking tablets containing preparations of pomegranate fruit extract and rhizome of greater galangal.121,171 A gel prepared with Solanum undatum plant extract is being tested for its safety and efficacy in patients of actinic keratoses (NCT01516515; NCT02559934), vulvar pre-cancerous lesions and cutaneous condyloma (NCT01676792). Mistletoe plant extract has been assessed for its ability to improve immune function in stage IV lung cancer patients receiving conventional chemotherapy (NCT00079794). Its use as a complementary treatment led to chemotherapy dose reductions, fewer hospitalisations and reduction in non-haematological side-effects.172 Plant extracts have been tested for their ability to provide relief against nasopharyngitis and upper respiratory tract infection (EudraCT Number: 2005-005207-4). A combined herbal preparation of dry ivy leaf extract, decoction of thyme and aniseed, and mucilage of marshmallow root was tested for its efficacy and tolerability in open clinical trial and this preparation alleviated cough in consequence of common cold, bronchitis or respiratory tract diseases with formation of mucus.173 Extract of Serenoa repens was analysed versus placebo in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (EudraCT Number: 2014-000222-38) and it was found effective in mitigating inflammatory biomarkers in these patients.174 Polyherbal formulations of neem and other plants in the form of cream or tablet have been tested for their anti-human papilloma virus (HPV) potential in women infected with HPV type 16.175
Neem leaf extract in herbal mouth rinse has been assessed for its effectiveness in controlling radiation induced mucositis in oral cancer patients (CTRI.2014/11/005163; NCT01898091). A randomised placebo-controlled clinical trial revealed alleviation of symptoms associated with osteoarthrits of the hip and knee with the use of an extract of *Artemisia annua* (ACTRN12614000259640). Although, these studies have met with mixed results, however, positive results obtained in these trials certainly pave a way ahead for plant based medicine to be incorporated with conventional medicine.

4. Surmounting the challenges faced by botanicals

4.1. Improving procedures and guidelines

Although, not strictly followed by all countries, protocols for safety and toxicity testing have been devised by several agencies including Union of Pure and Applied Chemistry, European Medicines Agency (EMA), and the European Food Safety Authority. Considering the complexity of herbal medicines viz a viz their content and action, organisations like WHO, European Agency for the Evaluation of Medicinal Products and European Scientific Cooperation of Phytomedicine, US Agency for Health Care Policy and Research, European Pharmacopoeia Commission, Department of Ayurveda, Yoga, Unani, Siddha, Homeopathy (India) are revising procedures and developing new protocols to standardise phytotherapy. Attempts are being made to resolve issues that occur due to nomenclature problems. Kew’s Medicinal Plant Names Services has developed a freely accessible global resource that provides information about plant and plant products relevant to policy making and health regulation, traditional medicine, functional foods and pharmacological research. This database provides information of medicinally relevant plants pertaining to their frequently used vernacular, trade and pharmaceutical names. The Uppsala Monitoring Centre (UMC) in collaboration with the Royal Botanic Gardens has established an effective system for standardisation and cross-referencing of herbal names in order to enable international reporting of ADRs due to herbal drugs. UMC has also been involved in developing the WHO herbal dictionary which serves as an international reference source of herbal products. This dictionary allows identification of herbal products, their bioactive constituents, possible therapeutic uses, coding and analysis of drug safety data during pre and post marketing. Herbal monographs have been published by American Herbal Pharmacopoeia, WHO, United States Pharmacopoeia, European Pharmacopoeia, EMA, Indian Pharmacopoeia etc.

Emphasis is being laid to improve the quality of ADR reporting and specialised centres have been set up worldwide for assistance in herbal pharmacovigilance. In USA, since herbal products are sold as dietary supplements and not as drugs therefore they are spared from pharmacovigilance obligations. However, health care practitioners and consumers are being made aware of the benefits of ADR reporting and are being guided to report ADR events to the FDA MedWatch Scheme. In UK, Medicines and Healthcare Products Regulatory Agency has a system for reporting of ADRs. In the EU, when any herbal product is classified as a medicine then the manufacturers have pharmacovigilance obligations listed under European directives and other national regulations. This includes informing the regulatory agencies of any untoward or unexpected effects. In UK, the Chinese Medicine Advisory Service with the help of Royal Botanic Gardens Kew helps with the enquiries on adverse effects and the identification of the Chinese medicinal herb suspected to be causing the effect. In Hong Kong toxicology centres in hospitals take up multidisciplinary investigations related to herbal toxicity. WHO Collaborating Centre for monitoring drug safety (UMC) collects ADR reports from over 100 countries and collates them with the purpose of addressing nomenclature issues and possibly co-relating the ADR with the correct herb. The database maintained by the UMC also provides useful information on the pharmacokinetic and pharmacodynamic drug interactions. Regulatory agencies around the world have started making efforts to facilitate the harmonization of regulatory requirements. The Association of Southeast Asian Nations (ASEAN) consists of ten member countries each with its varying backgrounds of traditional medicine. ASEAN has formed a harmonized regulatory framework for traditional and HMPs. This framework includes common agreements on additives, excipients, pesticide residue levels, labelling requirements etc.

4.2. Improving trial design and ensuring quality control

High quality scientific research intended for the safety and efficacy of HMPs is essential to instil confidence in practitioners of conventional medicine to adopt HMPs as alternatives for disease management. However, the high costs of research and development deter the manufacturers of herbal products from delving into this space. This deterrent can be surmounted by applying for a patent. Although, it is difficult to claim exclusive rights for growing herbs, spices, plants etc, however, this should not dissuade the manufacturers from venturing into HMP research since patents can also be granted on the basis of novelty related to processing and formulating HMP, unique compositions and their intended use for a medical purpose. Patents have been granted for HMP based on novel poly herb compositions, dosage forms, establishment of new processes for isolation and standardization of active compounds.

Clinical trials carried out with placebos and/or reference medicines before marketing are very important in revealing potential adverse effects emanating from the use of a particular drug. However, these clinical trials are of a short duration and are incapable of providing information on problems (such as long term effects) that are not comprehensively addressed by clinical trial protocols. Therefore, to evaluate long term toxicity and safety potentials, long-term carcinogenicity tests, reproductive and teratogenicity potentials should be assessed. Moreover, many a times some rare and severe adverse effects resulting due to interactions with drugs and nutrients come to the forefront in subgroups of people not included in the randomized control trials (RCTs). Such events are likely to be detected only when the drug is in use by a larger section of the population. Post-marketing surveillance of HMPs could help in keeping track of such effects.
The researchers should resort to high quality clinical trials and adhere to good reporting. Considering the shortfalls in trial reporting, the CONSORT statement has been amended with an aim to improve research and reporting quality with botanicals. Recommendations have been made with context to complete and transparent reporting of trials.\textsuperscript{57,189,190} Due emphasis has been laid on the standardization of the HMP because many a times the amount of the active ingredient is not known and is known to vary between preparations.\textsuperscript{60,191,192} The researchers must fully describe the preparation of placebos used in HMP trials so as to enable other researchers in carrying out related placebo-controlled trials in order to control bias that may occur due to the peculiar organoleptic properties of clinical preparations and their respective placebos.\textsuperscript{193} Caution must be practiced while designing clinical trials, laying stress on the internal and external validity of the tests used thereof. It is essential that the output of the results in the control conditions of the study find relevance in being used outside the experimental settings of the study (refers to the harmony between internal and external validity). This implies that the study findings give meaningful insights when applied in the ‘real’ situations.\textsuperscript{194,195} Further, for the results to be externally valid it must be ensured that the disease criteria for inclusion and exclusion should be relevant with the diagnostic procedures currently used.\textsuperscript{48} Cluster RCTs may be designed in order to establish the variabilities of the practitioners while evaluating the efficacy of the HMPs.\textsuperscript{48}

It is known that ayurveda recommends personalized treatment on the basis of an individual’s ‘prakriti’ and ‘tridoshas’. ‘Ayugenomics’ is an upcoming field of study which serves to bridge the gaps between genomic influences and Ayurvedic principles. It is an integration of principles of genomics with that of ayurveda and is aimed at studying inter-individual differences to disease development and therapeutics by interrelating their psychosomatic constitution and their genetic makeup.\textsuperscript{196,197} Such integration of disciplines could help in designing trials with ayurvedic remedies.

As defined by the EMA, chemical markers are chemically defined constituents or group of constituents intended for the control of quality. Chemical markers are employed in the standardization process to ensure that all batches contain a defined amount of the active ingredient. The choice of the chemical marker/s is essential to the quality of the herbal product. These could be of two types: active markers and analytical markers. Active markers possess therapeutic potentials while the latter ones are solely used for analytical purposes and have no therapeutic value.\textsuperscript{198} It must be understood that using a single active marker may not give a true representation of the synergistic effects of the various bioactive constituents present in the HMP.\textsuperscript{199,200} And similarly, using an inappropriate analytical marker may not appropriately give the indication of the potency or quality of HMP. Using a non-specific analytical marker (e.g. quercetin, oleanolic acid etc) will fail to recognize an adulterated HMP because of the widespread presence of the marker being used.\textsuperscript{201,202} Using a chemical marker alone for standardization and quality control of HMP has its disadvantages. Therefore, other methods must be used in tandem.

Chromatographic fingerprinting is an analytical method that employs high performance liquid chromatography, thin layer chromatography (TLC), and gas chromatography techniques.\textsuperscript{193,199,203} These techniques give a fingerprint which is unique to a HMP. This fingerprint comprises of a set of peaks which are characteristic of the herbal ingredients present. Thus, a unique fingerprint generated helps in qualitative and quantitative analysis. Principal component analysis can be used to compare fingerprint patterns to detect adulteration.\textsuperscript{203,204} For polyherbal preparations\textsuperscript{204,205} and preparations with closely related species (e.g. \textit{Heracleum sp}, \textit{Hyalanthus sibiricum}),\textsuperscript{206} a single chromatographic analysis may be insufficient. To resolve the details of polyherbal formulations 2D-TLC,\textsuperscript{206,207} multiple chromatographic fingerprinting\textsuperscript{203,154,193,204} and metabolite fingerprinting are advisable.\textsuperscript{205,208–210}

The regulators should perform targeted chemical analysis on every batch of HMPs to check for adulterants. To evade detection, manufacturers have started adding chemical drugs or their modified analogues to the capsule shells.\textsuperscript{211–213} In order to detect adulteration of this sort, reference spectra of these shells and analogues should be recorded with the aid of analytical techniques like liquid chromatography–mass spectrometry (LC–MS),\textsuperscript{214,215} nuclear magnetic resonance spectroscopy,\textsuperscript{215,216} infra-red spectroscopy.\textsuperscript{217} Considering the transnational movement of HMPs, it is required that the regulators and manufacturers involve in information sharing relating to detection of adulterants. Consumers can play their part by buying HMPs from reputable and trust worthy sources. In order to grapple with the unethical manufacturers and miscreants the consumers should be particular about details such as manufacturing and expiry dates, batch numbers, names and addresses of HMP manufactures. Having clear product categorization will enable sufficient safety checks. It is known that regulated HMPs are equipped with better product information details enabling the customers to make more informed choices, thus promoting the safe use of HMPs. With the growing popularity of HMPs and its worldwide acceptance, it is required that authorities harmonize their regulatory requirements so as to bring about transparency and convenience for manufacturers and consumers.

For the standardization of herbal drugs, tests can be applied based on several established standards including pharmacopeial standards, marker based phytochemical assays, process control standards, storage standards, polyherbal reference standards, chemi-informatics approaches based structural standards\textsuperscript{217} which include a range of physical, chemical and biological tests. Correct identification of plant involves ascertaining the correctness of the plant chosen based on its taxonomical classification, its morphological features etc. The part of plant to be used should be confirmed by matching its characteristic botanical features. Also, assessing the level of exposure of the plant part to the environment helps in deciding the levels of adulterants/contaminants.\textsuperscript{218} Removal of foreign organic matter involves removing other organic matter (like weeds etc) that may sometimes come along with the raw plant material. This is essential to avoid interference during the standardization. Estimation of ash values (total ash, sulphated ash, water soluble ash, acid insoluble ash) should be done by performing thermo-gravimetric
analysis, differential thermal analysis and differential scanning calorimetry.\textsuperscript{219–221} Moisture content must be determined precisely to assess the actual weight of the drug. Low moisture content increases the stability of the drug.\textsuperscript{217} Extractive values which are indicative of the extractable chemical constituents of the crude drug (under different solvent conditions) must be evaluated as they are important in dose calculation. The qualitative analysis of the crude drug involves screening of the various phytochemical constituents like flavonoids, alkaloids, phenolics, carbohydrates etc which are of pharmacological significance.\textsuperscript{222} LC-MS has previously been employed to standardize an aqueous extract of the mixture of twenty herbs. This method provided twenty chemical compounds to be used as reference markers.\textsuperscript{223,224} Quantitative analysis should be performed for the levels of different elements, minerals, heavy metals etc. Microbial assays should be carried out to establish the presence of mycotoxins, harmful fungi, bacteria and other microorganisms. Toxicology studies should be performed in relevant animal models to generate LD50 values and other relevant parameters which are required for subsequent studies by the drug regulators. These give information about potentially toxic elements, pesticide levels etc.\textsuperscript{203,225} In order to ensure process control standards, batch analysis should be done by performing intermediate testing using appropriate methods. Tests should be performed to check for any process induced toxicity and impurity. Storage standards should also be applied by determining storage standard markers for raw material, stable intermediates from fractions, processed material, and finished product. The shelf life of the finished product in various conditions of temperature, humidity should be also determined. Packaging material and labeling standards should also be checked.\textsuperscript{217} Polyherbal reference standards are established by comparing the reference standard of a single constituent in exclusion and its profile in polyherbal formulations. Chemi-informatic approaches include activity descriptors and its correlation modeling with poly-constituent profile based indicators.

For the safe and effective use of quality botanicals, it is utmost necessary that strict pre-market and post-market evaluation is carried out. The dealers of the herbal products (manufacturers, packagers, distributors, sellers etc) should be made to satisfy specific legal requirements such as GMP, ADR etc associated with the use of their HMPs. It is beyond doubt that quality of starting material affects HMP quality. Therefore, good agricultural practices (GAP) should be followed along with GMP. In many countries, the manufacturers have to conform to GMP before a license can be granted for production of HMP, although GAP is not legally mandatory for cultivators and manufacturers.\textsuperscript{68} To ensure good quality of HMP’s compliance to both GMP and GAP should be made mandatory. Medicinal plant cultivation through contract farming would ensure the quality of the produce and minimise the variability in plant preparations and maintain good quality products.

Through well designed educational and awareness programmes people need to be informed about the possible good and adverse effects of NHPs. Health care practitioners/clinicians also need to be provided in depth knowledge about medicinal plants/herbs and their putative health effects. A better interaction between the clinicians and patients with efficient exchange of information would help reinstate the efforts that are being put to establish the database of plant based medicine.

5. Conclusion

The growing popularity of over-the-counter available health products, dietary supplements, nutraceuticals obtained from plants has highlighted certain issues which need to be addressed at priority. These polychemical mixtures containing many pharmacologically active compounds need a thorough scientific and clinical evaluation in order to bring them to mainstream therapeutics. The perception of natural being safe can only be realised if these products are manufactured under strict regulatory controls and assessed for their efficacy. Through implementation of good agricultural, manufacturing and supply practices it would be possible to improve the quality of herbal medicines making them of a reproducible quality. A collaborative effort of the researchers, clinicians and patients is required to successfully establish herbal medicine in health promotion and disease management. Although evidences exist for the beneficial effects of plants against diseases and in health promotion, however the use of plant derived preparations can only be realised after the affirmation of their safety and efficacy. With such reassurances it could be possible to replace some synthetic drugs with herbal medicines or use them in combination with other drugs; thus enabling their integration into contemporary medicine.

Conflict of interest

Authors declare no conflicts of interest.

References

1. Winslow LC, Kroll DJ. Herbs as medicines. Arch Intern Med 1998;158:2192–9.
2. Fowler A, Koutsoni Y, Sommer V. Leaf-swallowing in Nigerian chimpanzees: evidence for assumed self-medication. Primates 2007;48:73–6.
3. Krief S, Jamart A, Mahe S, Leendertz FH, Mätz-Rensing K, Crespeau F, et al. Clinical and pathologic manifestation of oesophagostomosis in African great apes: does self-medication in wild apes influence disease progression. J Med Primatol 2008;37:188–95.
4. Raman R, Kundula S. Zoopharmacognosy: self medication in wild animals. Resonance 2008;245–53.
5. Barden J, Weaver DF. The rise of micropharma. Drug Discov Today 2010;15:84–7.
6. Maridass M, John de Britto A. Origins of plant derived medicines. Ethnobotanical Leaflets 2008;12:373–87.
7. Gordaliza M. Terpenyl-purines from the sea. Marine Drugs 2009;833–49.
8. Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 2014;79:629–61.
9. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012;75:311–35.
10. Ovadje P, Roma A, Steckle M, Nicoletti I, Arnason JT, Pandey S. Advances in the research and development of natural health products as main stream cancer
therapeutics. Evid Based Complement Alternat Med 2015;2015.

11. Pan SY, Zhou SF, Gao SH, Yu ZL, Zhang SF, Tang MK, et al. New perspectives on how to discover drugs from herbal medicines: CAM’s outstanding contribution to modern therapeutics. Evid Based Complement Alternat Med 2013;2013, 25 p.

12. Sasidharan S, Chen Y, Saravanan D, Sundram KM, Yoga Latha L. Extraction, isolation and characterization of bioactive compounds from plants’ extracts. AJTCAM 2011;8:1–10.

13. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2013;4:1–10.

14. Gopal NM, Tejaswini J, Mantry S, Kumar SA. International standards of medicinal plants. IJPSR 2014;2:2498–532.

15. Robinson MM, Zhang X. The world medicines situation 2011. WHO; 2011.

16. World Health Organization (WHO). National policy on traditional medicine and regulation of herbal medicines. Geneva: World Health Organization (WHO); 2005. Report of WHO global survey.

17. Benzie IF, Wachtel-Galor S. Herbal medicine: biomolecular and clinical aspects. 2nd ed. Boca Raton (FL): CRC Press/Taylor & Francis; 2011.

18. De Smet P. Herbal medicine in Europe: relaxing regulatory standards. N Engl J Med 2005;352:1176–8.

19. Tilburt JC, Kapchuk TJ. Herbal medicine research and global health: an ethical analysis. Bull World Health Organ 2008;86:577–656.

20. Pan SY, Gao SH, Zhou SF, Tang MK, Yu ZL, Ko KM. New perspectives on complementary and alternative medicine: an overview and alternative therapy. Altern Ther Health Med 2012;18:20–36.

21. Weeks LC, Strudholm T. A scoping review of research on complementary and alternative medicine (CAM) and the mass media: looking back, moving forward. BMC Complement Altern Med 2008;8:43.

22. WHO traditional medicine strategy 2014–2023. WHO; 2013.

23. Rinaldi A, Shetty P. Review: The facts, figures and challenges of mixing modern and traditional medicine; 2015. Available from: http://www.scidiv.net/global/medicine/feature/traditional-medicine-modern-times-facts-figures.html.

24. Yirga G, Teferi M, Kasaye M. Survey of medicinal plants used to treat human ailments in Hawzen district, Northern Ethiopia. Int J Biodivers Conserv 2011;3:799–14.

25. Sahoo N, Manchikanti P, Dey S. Herbal drugs: standards and regulation. Fitoterapia 2010;81:462–71.

26. Rettner R. Herb supplements are the most common complementary medicine in US; 2014. Available from: http://www.livescience.com/44866-herb-supplements-complementary-medicine.html.

27. Arora N, Koul A. A ‘complex solution’ to a ‘complex problem’: tackling the complexity of cancer with botanicals. Eur J Cancer Prev 2014;23:568–78.

28. Kumar S, Dobos GJ, Rampp T. The significance of Ayurvedic medicinal plants. J Evid Based Complement Alternat Med 2016;1–8.

29. Chopra A, Saluja M, Tilku G. Ayurveda–modern medicine interface: a critical appraisal of studies of Ayurvedic medicines to treat osteoarthritis and rheumatoid arthritis. J Ayurveda Integr Med 2010;1:190–8.

30. Garodia P, Ichikawa H, Malani N, Sethi G, Aggarwal BB. From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer. J Soc Integr Oncol 2007;5.

31. Bhandaria M, Ravipati AS, Reddy N, Koyyalamudi SR. Traditional ayurvedic medicines: pathway to develop anti-cancer drugs. J Mol Pharm Org Process Res 2015;3(3):100130; http://dx.doi.org/10.4172/2239-9053.100130.

32. Bandaranayake WM. Quality control, screening, toxicity and regulation of herbal drugs. Modern phytomedicine: Turning medicinal plants into drugs. Weinheim: Wiley-VCHGmbH & Co.KGaA; 2006:25–57.

33. Vickers A, Zollman C, Lee R. ABC of complementary medicine: herbal medicine. BMJ 1999;319:1050–3.

34. Zollman C, Vickers A, Richardson J, editors. ABC of complementary medicine. 2nd ed. Wiley Blackwell; 2008.

35. Patterson RE, Neuhauser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ. Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 2003;103:323–8.

36. Globe Newswire. 2015. Available from: http://globenewswire.com/news-release/2015/04/23/727513/10130416/en/Dietary-Supplements-Marketis-Expected-to-Reach-US-179-8-Billion-Globally-in-2020-Persistence-Market-Research.html.

37. Paller CJ, Denmeade SR, Carducci MA. Challenges of conducting clinical trials of natural products to combat cancer. Clin Adv Hematol Oncol 2016;14:447–55.

38. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol 2010;55:515–29.

39. Ventola CL. Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States. Part 1: The widespread use of CAM and the need for better-informed health care professionals to provide patient counseling. PT 2010;35:461–8.

40. Bauer I, Guerra JJ. Physicians’ knowledge and communication about traditional, complementary and alternative medicine use among Latino patients at Kaiser Permanente, Oakland CA. Field Actions Sci Rep 2014;8.

41. Hilal M, Hilal S. Knowledge, attitude, and utilization of herbal medicines by physicians in the Kingdom of Bahrain: a cross-sectional study. J Assn Arab Univ Basic Sci 2017;24:325–33.

42. Lee RT, Barbo A, Lopez G, Melhem-Bertrandt A, Lin H, Olopade OI, et al. National survey of US oncologists’ knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol 2014;32:4095–101.

43. Reddy KR, Belle SH, Fried MW, Afsha N, Navarro VJ, Hawke RJ, et al. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. Clin Trials 2012;9:102–12.

44. Thatte UM. Clinical research with ayurvedic medicines. Pharma Times 2005;37:9–10.

45. Parveen A, Parveen B, Parveen R, Ahmad S. Challenges and guidelines for clinical trial of herbal drugs. J Pharm Bioallied Sci 2015;7:329–33.

46. Kaur R, Gupta V, Christopher AF, Bansal P. Scope and bottlenecks in clinical trials of herbal drugs–present scenario. J Pharm Res 2015;14:26–32.

47. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Int Med 2001;8:135.

48. Mutua DN, Juma KK, Munene M, Njage EN. Safety, efficacy, regulations and bioethics in herbal medicines research and practice. J Clin Res Bioethics 2016;7:3.

49. Dhanakuar SA, Thatte UM. Current status of ayurveda in phytomedicine. Phytomedicine 1997;4:359–68.

50. Bower H. Double standards exist in judging traditional and alternative medicine. Br Med J 1998;316:1694.

51. Lu A. GP-TCM RA Clinical Studies Interest Group – A Draft Plan for Action; GP-TCM RA Clinical Studies Interest Group.
Available from: http://www.mp-tcm.org/work-packages/wp6-functional-genomics-in-clinical-studies-of-chinese-herbal-medicines/
52. Moreira DL, Teixeira SS, Monteiro MHD, De-Oliveira ACAX, Paunggarten FJR. Traditional use and safety of herbal medicines. Rev Bras Farmacogn 2014;24:248–57.
53. Linde K, Jonas WB, Melchart D, Willich S. The methodological quality of randomized controlled trials of homeopathy, herbal medicines and acupuncture. Int J Epidemiol 2001;30:526–31.
54. Srinivasan K. Spices as influencers of body metabolism: an overview of three decades of research. Food Res Int 2005;38:77–86.
55. Claraco AE, Hanna SE, Fargas-Babjak A. Reporting of clinical details in randomized controlled trials of acupuncture for the treatment of migraine/headaches and nausea/vomiting. J Altern Complement Med 2003;151–9.
56. Bian ZX, Li YP, Moher D, Dagenais S, Liu L, Wu TX, et al. Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology. J Chin Integr Med 2006;4:120–9.
57. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol 2006;59:1134–49.
58. Linde K, Willich SN. How objective are systematic reviews? Differences between reviews on complementary medicine. J R Soc Med 2003;96:617–22.
59. Davidson E, Vlachojannis J, Chrubasik MS. Best available evidence in Cochrane reviews on herbal medicines. Evid Based Complement Alternat Med 2013:1–7.
60. Liu ZL, Xie LZ, Zhu J, Li GQ, Grant SJ, Liu JP. Herbal medicines for fatty liver diseases. Cochrane Database Syst Rev 2013;8:CD009059.
61. Linde K, Barret B, Wolkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2006;25:CD00530.
62. Miyasaka LS, Atallah AN, Soares BG. Valerian for anxiety disorders. Cochrane Database Syst Rev 2006;4:CD004515.
63. Miyasaka LS, Atallah AN, Soares BG. Passiflora for anxiety disorder. Cochrane Database Syst Rev 2007;1:CD004518.
64. Dat AD, Poon F, Pham KBT, Douat J. Aloe vera for treating acute and chronic wounds. Cochrane Database Syst Rev 2012;2:CD008762.
65. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012;12:CD007924.
66. Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003;18:451–71.
67. Wider B, Pittler MH, Thompson-Coon J, Ernst E. Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst Rev 2013;28:CD003355.
68. Wah CL, Hock SC, Yun TK. Current scientific status and regulatory control of traditional/herbal medicinal products: globalisation challenges. Pharm Eng 2012;32.
69. Qi GD, We DA, Chung LP, Fai CK. Placebos used in clinical trials for Chinese herbal medicine. Recent Pat Inflamm Allergy Drug Discov 2008;2:123–7.
70. Willcox M, Benoit-Vical F, Fowler D, Bourdy G, Burbord G, Giani S, et al. Do ethno- and experimental and laboratory data predict clinical safety and efficacy of anti-malarial plants? Malaria J 2011;10:S7.
71. Willcox M, Siegfried N, Johnson Q. Capacity for clinical research on herbal medicines in Africa. J Altern Complement Med 2012;18:622–8.
72. Herper M. The cost of creating a new drug now $5 billion, pushing Big Pharma to change; 2013. Available from: http://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/.
73. Wayneugarden W. The economics of pharmaceutical pricing; 2014. Available from: https://www.pacificresearch.org/fileadmin/documents/Studies/PDFs/2013-2015/PharmaPricingG.pdf.
74. Derendorf H. Pharmacokinetics of natural compounds. Planta Med 2012;78:IL41, http://dx.doi.org/10.1055/s-0032-320228.
75. Lee RT, Barbo A, Lopez G, Melhem-Bertrandt A, Lin H, Olopade OI, et al. Celin National survey of US oncologists’ knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol 2014;32:4005–10.
76. Coates PM, Paul MC, Blackman, Blackman MR, Cragg GM, Levine M, White JD, Moss J, Levine MA, editors. Encyclopaedia of dietary supplements. New York, NY: Marcel Dekker; 2010.
77. Scott EN, Gescher AJ, Steward WFP. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res 2009;2:525–30.
78. Bhattaram VA, Grafe U, Kohlert C, Veit M, Derendorf H. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 2002;3:1–33.
79. Cho HJ, Yoon IS. Pharmacokinetic interactions of herbs with cytochrome P450 and P-glycoprotein. Evid Based Complement Alternat Med 2015:10. Article ID 736431.
80. Bailey DG, Dresser G. Natural products and adverse drug interactions. CMAJ 2004;170:1531–2.
81. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268–9.
82. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John’s wort. Lancet 2000;355:547–8 [published erratum appears in Lancet 2001;357:1210].
83. Ruschitzka F, Meier PJ, Turina M, Luscher TT, Noll G. Acute heart transplant rejection due to St John’s wort. Lancet 2000;355:548–9.
84. Nicholas ET, Dzobo K, Chopera D, Wonkam A, Skelton M, Blackhurst D, et al. Pharmacogenomics implications of using herbal medicinal products on African populations in health transition. Pharmaceuticals (Basel) 2015;8:637–63.
85. Sharma AK, Kumar R, Mishra A, Gupta R. Problems associated with clinical trials of Ayurvedic medicines. Braz J Pharmacogn 2010;20:276–81.
86. Kunle OF, Egbarebva HO, Ahmadu PO. Standardization of herbal medicines – a review. Int J Biodeviers Conserv 2012;4:101–12.
87. Dharmananda S. Dosage and forms of herbs: Decoctions, Dried Decoctions, Powders, Pills, Etc. Available from: http://www.itmonline.org/arts/dosage.htm.
88. Tomé-Carneiro J, Larrosa M, González-Sarrías A, Tomás-Barberán F, García-Conesa MT, Espin JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des 2013;19:6064–93.
89. Xu Q, Feng Y, Duez P, Hendry BM, Hylands P. The hunt for antibiotic and probiotic botanicals. Science 2014;346:S19–20.
90. Shetti S, Kumar CD, Srikwastava NK, Sharma JP. Pharmacovigilance of herbal medicines: current state and future directions. Pharmacogn Mag 2011;7:69–73.
91. Walj R, Boon H. Natural health product regulations: perceptions and impact. Trends Food Sci Technol 2008;19:494–7.
92. Silano V, Coppens P, Larranaga-Guetaña A, Minhetti P, Roth-Ehrang R. Regulations applicable to plant food
supplements and related products in the European Union. Food Funct 2011;2:710–9.
93. Avigan MJ, Mizersky RR, Seeff LB. Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States. Int J Mol Sci 2016;17:331.
94. FDA. FDA regulation of drugs vs dietary supplements; 2015. Available from: http://www.cancer.org/treatment/treatmentsandsideeffects/complementaryandalternative/medicine/dietarysupplements/dietary-supplements-fda-regulations.
95. Bazzi KL, Witmer DR, Pinto B, Bush C, Clark J, Deffenbaugh Jr J. National survey of dietary supplement policies in acute care facilities. Am J Health Syst Pharm 2006;63:65–70.
96. Shaw D, Ladds G, Duez P, Williamson E, Chan K. Pharmacovigilance of herbal medicine. J Ethnopharmacol 2012;140:513–8.
97. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Drautw M, Jadoul M, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;34:387–91.
98. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identification of aristolochic acid in Chinese herbs. Lancet 1994;343:174.
99. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008;74:158–69.
100. European Medicines Agency (EMA). Public statement on the risks associated with the use of herbal products containing aristolochia species; 2005. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089597.pdf.
101. Cheung TP, Xue C, Leung K, Chan K, Li CG. Aristolochic acids detected in some raw Chinese medicinal herbs and manufactured herbal products—a consequence of inappropriate nomenclature and imprecise labelling? Clin Toxicol (Philad) 2006;44:371–8.
102. Martena MJ, van der Wielen JC, van de Laak LF, Konings EJ, de Groot HN, Rietjens JM. Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Anal Bioanal Chem 2007;389:263–75.
103. Jordan SA, Cunningham DG, Marles RJ. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol 2010;243:198–216.
104. Medicines and Healthcare Products Regulatory Agency. Prohibited or restricted herbal ingredients; 2011. Available from: http://www.mhra.gov.uk/howweregulate/medicines/herbal-medicinesregulation/prohibitedrestrictedherbalingredients/index.htm.
105. Vohra S, Cvijovic K, Boon H, Foster BC, Jaeger W, LeGatt D, et al. Study of Natural Health Product Adverse Reactions (SONAR): active surveillance of adverse events following concurrent natural health product and prescription drug use in community pharmacies. PLoS ONE 2012;7:e45196.
106. Charrois TL, Hill BL, Yu D, Foster BC, Boon HS, Cramer K, et al. Community identification of natural health product drug interactions. Ann Pharmacother 2007;41:1124–9.
107. Winslow LG, Shapiro H. Physicians want education about complementary and alternative medicine to enhance communication with their patients. Arch Intern Med 2002;162:1176–81.
108. Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal medicines and conventional OTC medicines: face-to-face interviews with 515 users of herbal medicines. Br J Clin Pharmacol 1998;45:496–500.
109. van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists’ role in reporting adverse drug reactions in an international perspective. Pharrmacopoemiol Drug Saf 2004;13:457–64.
110. Vickers KA, Jolly KB, Greenfield SM. Herbal medicine: women’s views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med 2006;6:1–8.
111. Tiralong E, Braun L, Wilkinson JM, Spizer O, Bailey M, Poole S, et al. Exploring the integration of complementary medicines into Australian pharmacy practice with a focus on different practice settings and background knowledge. J Complement Integ Med 2010;7:1–21.
112. Coulter DM. PEM in New Zealand. In: Mann RD, Andrews EB, editors. Pharmacovigilance. Chichester: Wiley; 2002:345–62.
113. Shakir SAW. PEM in the UK. In: Mann RD, Andrews EB, editors. Pharmacovigilance. Chichester: Wiley; 2002:333–44.
114. ICHs Steering Committee. ICH harmonized tripartite guideline, pharmacovigilance planning. 2004. Available from: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2/E2e_Guideline.pdf.
115. McMlenon DJ, Bond CM, Hannaford PC, Watson AJ, Lee L, Avery HA. Adverse drug reaction reporting in the UK. Drug Saf 2010;33:775–86.
116. Garret RG. Natural sources of metals in the environment. Proc Int Symp Metal Ions Biol Med 2000;6:508–10.
117. Street RA. Heavy metals in medicinal plant products—an African perspective. S Afr J Bot 2012;82:67–74.
118. Bauer R, Tittel G. Quality assessment of herbal preparations as a precondition of pharmacological and clinical studies. Phytomedicine 1996;2:193–8.
119. McLaren J, Swift W, Dillon P, Allsop S. Cannabis potency and contamination: a review of the literature. Addiction 2008;103:1100–9.
120. Ulbricht C, Chao W, Costa D, Nguyen Y, Seamon E, Weissner W. An evidence-based systematic review of green-lipped mussel (Perna canaliculus) by the Natural Standard Research Collaboration. J Diet Suppl 2009;6:54–90.
121. Armbruster N, Bryan K, Costa D, Giese N, Gruenwald J, Iovin E, et al. Cinnamon (Cinnamomum spp.). Natural Standard Professional Monograph; 2012. Available from: http://www.naturalstandard.com/databases/herbsupplements/all/cassia.asp.
122. Wang GW, Hu WT, Huang BK, Qin LP. Illicium verum: a review on its botany, traditional use, chemistry and pharmacology. J Ethnopharmacol 2011;136:10–20.
123. Ernst E. Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review. J Intern Med 2002;252:107–13.
124. Ernst E. Cardiovascular adverse effects of herbal medicines: a systematic review of the recent literature. Can J Cardiol 2003;19:818–27.
125. Lynch E, Braithwaite R. A review of the clinical and toxicological aspects of ‘traditional’ (herbal) medicines adulterated with heavy metals. Expert Opin Drug Saf 2005;4:769–78.
126. Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 2003;18:451–71.
127. Affum O, Shiloh DO, Adomako D. Monitoring of arsenic levels in some ready-to-use anti-malaria herbal products from drug sales outlets in the Madina area of Accra, Ghana. Food Chem Toxicol 2013;56:131–5.
128. Cohen PA, Ernst E. Safety of herbal supplements: a guide for cardiologists. Cardiovasc Ther 2010;28:246–53.
129. Posadzki P, Watson E. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. Eur J Clin Pharmacol 2013;69:295–307.

130. WHO. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues; 2007. Available from: http://apps.who.int/medicinedocs/documents/s14878e/s14878e.pdf.

131. Rao MM, Meena AK, Galib G. Detection of toxic heavy metals and pesticide residue in herbal plants which are commonly used in the herbal formulations. Environ Monit Assess 2011;181:267–71.

132. Prakash O, Jyoti KA, Kumar P, Manna NK. Adulteration and substitution in Indian medicinal plants: an overview. J Med Plants Stud 2013;1:127–32.

133. Ahmed S, Hasan MM. Crude drug adulteration: a concise review. World J Pharm Sci 2015;4:274–83.

134. Cheng W, Ko W, Fan SG, Song L, Bian ZX. Evidence-based management of herb–drug interaction in cancer chemotherapy. Explore 2010;6:324–9.

135. Callaway E. Screen uncovers hidden ingredients of Chinese medicine; 2012. Available from: http://www.nature.com/news/screen-uncovers-hidden-ingredients-of-chinese-medicine.1.10430.

136. Newmaster SG, Grigruc M, Shanmughanandhan D, Ramalingam S, Rugapathy S. DNA barcoding detects contamination and substitution in North American herbal products. BMC Med 2013;11:2–13.

137. Booker A. Up to 40% of some herbal supplements are mislabelled or contain adulterants; 2016. Available from: http://theconversation.com/up-to-40-of-some-herbal-supplements-are-mislabelled-or-contain-adulterants-63859.

138. Shahid U. Herbal treatment strategies for breast cancer. In: Malki AM, editor. Cancer treatment strategies. Foster City, CA, USA: OMICS Group Ebooks; 2014.

139. Rice T, Rosenau P, Unruth LY, Barnes AJ. Health systems in transition. In: Saltman RB, van Ginneken E, eds. Health system review. vol. 15. 2013.

140. Eskinazi D. Alternative medicine: definition, scope and challenges. ABPN 2001;5:19–25.

141. Ernst E, Cohen MH, Stone J. Ethical problems arising in evidence based complementary and alternative medicine. Med Ethics 2004;30:156–9.

142. Joos S, Glassen K, Musselmann B. Herbal medicine in primary healthcare in Germany: the patient’s perspective. Evid Based Complement Alternat Med 2012;2012. Article ID 294638, 10 p.

143. Reynolds D. More Medicare. Medicaid patients turning to alternative therapies? 2010. Available from: http://www.emaxhealth.com/1506/more-medicare-medicaidpatients-turning-alternative-therapies.html.

144. National Center for Complementary and Alternative Medicines (NCCAM). Paying for complementary and integrative health approaches; 2011. Available from: http://nccam.nih.gov/health/financial.

145. Shi L, Singh DA. Delivering health care in America: a systems approach. 5th ed. Boston, MA: Jones & Bartlett; 2012.

146. Wissener S, Falkenberg T, Hegyi G, Hök J, di Sarsina PR, Fanneba V. Legal status and regulation of CAM in Europe Part 1 – CAM regulations in the European countries/Legal status and regulation of complementary and alternative medicine in Europe. Forsch Komplementmed 2012;19:29–36.

147. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. Curr Sci 2004;86:789–99.

148. Dasgupta T, Banerjee S, Yadava PK, Rao AR. Chemopreventive potential of Azadirachta indica extract in murine carcinogenesis model. J Ethnopharmacol 2004;92:23–36.

149. Koul A, Gangar SC, Sandhir R. Pitfalls in journey from traditional to modern medicine. Nat Prod Rad 2005;4:6–14.

150. Gangar SC, Sandhir R, Rai DV, Koul A. Modulatory effects of Azadirachta indica on benzo(a)pyrene induced forestomach tumorigenesis in Balb/c mice. World J Gastroenterol 2006;12:2749–55.

151. Arora N, Koul A, Bansal MP. Chemopreventive activity of Azadirachta indica on two-stage skin carcinogenesis in murine model. Phytother Res 2011;25:408–16.

152. Bharati S, Rishi P, Koul A. Azadirachta indica exhibits chemopreventive action against hepatic cancer: studies on associated histopathological and ultrastructural changes. Micros Res Tech 2012;75:586–95.

153. Sharma C, Vas AJ, Goila P, Gheewala TM, Rizvi TA, Hassan A. Ethanolic neem (Azadirachta indica) leaf extract prevents growth of MCF-7 and HeLa cells and potentiates the therapeutic index of cisplatin. J Oncol 2014;321754.

154. Arumugam A, Agullo P, Boopalan T, Nandy S, Lopez R, Gutierrez C, et al. Neem leaf extract inhibits mammary carcinogenesis by altering cell proliferation, apoptosis, and angiogenesis. Cancer Biol Ther 2014;15:26–34.

155. Gupta P, Bansal MP, Koul A. Spectroscopic characterization of lycopene extract from Lycopersicum esculentum (tomato) and its evaluation as a chemopreventive agent against experimental hepatocarcinogenesis in mice. Phytother Res 2013;27:448–56.

156. Koul A, Goyal R, Bharati S. Protective effect of Azadirachta indica against Doxorubicin-induced cardiac toxicity in tumour bearing mice. Indian J Exp Biol 2014;52:323–31.

157. Koul A, Shubhbrant, Gupta P. Phytomodulatory potential of lycopene from Lycopersicum esculentum against doxorubicin induced nephrotoxicity. Indian J Exp Biol 2013;51:635–45.

158. Balas S, Chugh NA, Bansal SC, Garg ML, Koul A. Protective role of Aloe vera against X-ray induced testicular dysfunction. Andrologia 2017;49:e12697.

159. Gehlot P, Soyal D, Goyal PK. Alterations in oxidative stress in testes of Swiss albino mice by Aloe vera leaf extract after gamma irradiation. Pharmacology online 2007:359–70.

160. Kumar A, Kumar R, Rahman MS, Iqubal MA, Anand G, Niraj PK, et al. Phytoremedial effect of Withania somnifera against arsenic-induced testicular toxicity in Charles Foster rats. Avicenna J Phyto med 2015;5:355–64.

161. Li W, Zhang C, Du H, Huang V, Sun B, Harris JP, et al. suppresses the up-regulation of acetyl-coA carboxylase 1 and skin tumor formation in a skin carcinogenesis mouse model. Mol Carcinog 2016;55:1739–46.

162. Palliyaguru DL, Singh SV, Kessler TW. Withania somnifera: from prevention to treatment of cancer. Mol Nutr Food Res 2016;60:1342–53.

163. Sarbisehi M, Khani M, Salimi S, Valizadeh M, Sargolzaei AF. Anti proliferative and antioxidant effects of Withania coagulans extract on benign prostatic hyperplasia in rats. Nephrourrol Mon 2016;8:33180.

164. Turriani E, Calcabrini C, Sestili P, Catanzaro E, Gianni E, Díaz AR, et al. Withania somnifera induces cytotoxic and cytostatic effects on human T leukemia cells. Toxins (Basel) 2016.

165. Tulskulak J, Glueck B, Hinds TD, Shah ZA. Ginkgo biloba extract prevents female mice from ischemic brain damage and the mechanism is independent of the H01/Wnt pathway. Transl Stroke Res 2016;7:120–31.

166. Kaur S, Chhabra B, Nehru B. Ginkgo biloba extract attenuates hippocampal neuronal loss and cognitive dysfunction resulting from trimethylin in mice. PhytoMedicine 2013;20:178–86.

167. Ribeiro ML, Moreira LM, Arçari DP, Dos Santos LF, Marques AC, Pedrazzoli J, et al. Protective effects of chronic
treatment with a standardized extract of Ginkgo biloba L. in the prefrontal cortex and dorsal hippocampus of middle-aged rats. Behav Brain Res 2016;313: 144–50.

168. Zambrelam CR, Vendrasco NC, Oliveira DR, Caiardo RB, Cerutti SM. Effects of standardized Ginkgo biloba extract on the acquisition, retrieval and extinction of conditioned suppression: Evidence that short-term memory and long-term memory are differentially modulated. Physiol Behav 2016;165:55–68.

169. Chandra S, Sah K, Bagewadi A, Keluskar V, Shetty A, Ammanagi R, et al. Additive and synergistic effect of phytochemicals in prevention of oral cancer. Eur J Gen Dent 2012;1:142–7.

170. Miller PE, Snyder DC. Phytochemicals and cancer risk: a review of the epidemiological evidence. Nutr Clin Pract 2012;27:599–612.

171. Fedder MD, Jakobsen HB, Giversen I, Christensen LP, Parner ET, Fedder J. An extract of pomegranate fruit and galangal rhizome increases the numbers of motile sperm: a prospective, randomised, controlled, double-blind trial. PLOS ONE 2014;9:e108532.

172. Bar Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E, Haim N. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer 2013;49:58–64.

173. Büechi S, Vögelin R, von Eiff MM, Ramos M, Melzer J. Open trial to assess aspects of safety and efficacy of a combined herbal cough syrup with ivy and thyme. Forsch Komplementarmed Klass Naturheilkd 2005;12:328–32.

174. Latil A, Pétrissans MT, Rouquet J, Robert G, de la Taille A. Effects of hexanic extract of Serenos repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 2015;75:1857–67.

175. Shukla S, Bharti AC, Hussain S, Mahata S, Hedau S, Kailash A, et al. Elimination of high-risk human papillomavirus type HPV16 infection by ‘Praneem’ polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol 2009;135:1701–9.

176. Stebbings S. Trial to investigate the efficacy and safety of an extract of Artemisia annua administered over 12 weeks, for managing pain, stiffness, and functional limitation associated with osteoarthritis of the hip and knee. Clin Rheumatol 2016;35:1829–36.

177. Mosibuzzaman M, Choudhary ML. Protocols on safety, efficacy, standardization, and documentation of herbal medicine (IUPAC technical report). Pure Appl Chem 2008;80:2195–230.

178. European Medicines Agency (EMA). Herbal medicinal products. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ regulation/general/general_content_000208.jsp.

179. European Food Safety Authority (EFSA) guidance on safety assessment of botanicals and botanical preparations intended for use as ingredients in food supplements. Eur Food Saf Auth J 2009;7:1249.

180. Kew Royal Botanic Gardens. Medicinal plants names services. Available from: http://www.kew.org/kew-science/people-and-data/resources-and-databases/medicinal-plant-names-services.

181. UMC. 2011. Available at: http://www.who-umc.org/graphics/24727.pdf.

182. Strandell J, Caster O, Bate A, Norén GN, Edwards IR. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf 2011;34:253–66.

183. Association of South East Asian Nations. Harmonization of standards and technical requirements in ASEAN. Available from: http://www.asean.org/18215.htm.

184. Association of South East Asian Nations (ASEAN). Profile of definition, terminology and technical requirement of traditional medicines and health supplements among ASEAN member states. Available from: http://www.asean.org/20258.pdf.

185. Kartal M. Intellectual property protection in the natural product drug discovery, traditional herbal medicine and herbal medicinal products. Phytotherapy Res 2007;21:113–9.

186. Mustahba M, Babootta S, Athar TMD, Thajudeen KY, Ahmed S, Ali J. Patented herbal formulations and their therapeutic applications. Recent Pat Drug Deliv Formul 2010;4:231–44.

187. Wang X, Chan AW. Challenges and patenting strategies for Chinese herbal medicines. Chin Med 2010;5:24.

188. Sahoo N, Manchikanti P, Dey SH. Herbal drug patenting in India: IP potential. J Ethnopharmacol 2011;137:289–97.

189. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, CONSORT Group. Reporting randomized controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med 2006;144:364–7.

190. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Int J Surg 2011;9:673–7.

191. Wu T, Harrison RA, Chen X, Ni J, Zhou L, Qiao J, et al. Tongxinluo capsule for unstable angina pectoris. Cochrane Database Syst Rev 2006;4:CD004474.

192. Wolsko PM, Solondz DK, Phillips RS, Schachter SC, Eisenberg DM. Lack of herbal supplement characterization in published randomized controlled trials. Am J Med 2005;118:1087–93.

193. Zhang JI, Cui M, He Y, Yu HL, Guo DA. Chemical fingerprint and metabolic fingerprint analysis of Danshen Injection by HPLC-UV and HPLC-MS methods. J Pharm Biomed Anal 2005;36:1029–35.

194. Linde K, Jonas WB. Evaluating complementary and alternative medicine: the balance of rigor and relevance. In: Jonas WB, Levin JS, editors. Essentials of complementary and alternative medicine. Baltimore: Lippincott Williams & Wilkins; 1999:57–71.

195. Turner RB, Bauer R, Woelfert K, Hulse TC, Gangemi JD. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med 2005;353:341–8.

196. Gupta P. Pharmacogenetics, pharmacogenomics and ayurvedonics for personalized medicine: a paradigm shift. Indian J Pharm Sci 2015;77:135e141.

197. Jaiswal YS, Williams LL. A glimpse of Ayurveda: the forgotten history and principles of Indian traditional medicine. J Tradit Complement Med 2017;7:50–3.

198. European Medicines Agency. Reflection paper on marker used for quantitative and qualitative analysis of herbal medicinal products and traditional herbal medicinal products; 2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003211.pdf.

199. Tistaert C, Dejaegher B, Heyden YV. Chromatographic separation techniques and data handling methods for herbal fingerprints: a review. Anal Chim Acta 2011;690:148–61.

200. Zeng Z, Chau FT, Chan HY, Cheung CY, Lau TY, Wei S, et al. Recent advances in the compound oriented and pattern oriented approaches to the quality control of herbal medicine. Chin Med 2008;3:9.

201. Xie PS, Leung AY. Understanding the traditional aspect of Chinese medicine in order to achieve meaningful quality control of Chinese materia medica. J Chromatogr A 2009;1216:1933–40.
202. Crockett SL, Khan IA. Challenges of standardization: marker compounds in plant species related and unrelated to top selling herbs. J Herbs Spices Med Plants 2003;10:13–24.

203. Xie P, Chen S, Liang YZ, Wang X, Tian R, Upton R. Chromatographic fingerprint analysis—a rational approach for quality assessment of traditional Chinese herbal medicine. J Chromatogr A 2006;1112:171–80.

204. Fan XH, Cheng YY, Ye ZL, Lin RC, Qian ZZ. Multiple chromatographic fingerprinting and its application to the quality control of herbal medicines. Anal Chim Acta 2006;555:217–24.

205. Jiang Y, David B, Tu P, Barbin Y. Recent analytical approaches in quality control of traditional Chinese medicines—a review. Anal Chim Acta 2010;657:9–18.

206. Ciesla L, Bogucka-Kocka A, Hajnos M, Petruczynik A, Waksmundzka-Hajnos M. Two dimensional thin layer chromatography with adsorbent gradient as a method of chromatographic fingerprinting of furanocoumarins for distinguishing selected varieties and forms of Heracleum spp. J Chromatogr 2008;1207:160–8.

207. Ciesla L, Waksmundzka-Hajnos M. Two dimensional thin layer chromatography in the analysis of secondary plant metabolites. J Chromatogr A 2009;1216:1035–52.

208. Holmes E, Tang H, Wang Y, Seger C. The assessment of plant metabolite profiles by NMR-based methodologies. Planta Med 2006;72:771–85.

209. Krishnan P, Kruger NJ, Ratcliffe RG. Metabolite fingerprinting and profiling in plants using NMR. J Exp Bot 2005;56:255–65.

210. Kim HK, Choi YH, Erkelenz C, Lefeber AW, Verpoorte R. Metabolic fingerprinting of Ephedra species using 1H-NMR spectroscopy and principal component analysis. Chem Pharm Bull 2005;53:105–9.

211. Vennhuis B, Tan J, Vredenbergt MJ, Ge X, Low MY, de Kaste D. Capsule shells adulterated with Tadalafl. Forensic Sci Int 2012;214:20–2.

212. Health Sciences Authority. HAS warns against consuming “XP Tongkat Ali Supreme” capsules found to contain undeclared potent substances; 2009. Available from: http://www.hsa.gov.sg/content/hsa/en/News_Events/Press_Releases/2009/hsa.warns.against0.shtml.

213. Yuen YP, Lai CK, Poon WT, Ng SW, Chan AY, Mak TW. Adulteration of over-the-counter slimming products with pharmaceutical analogues—an emerging threat. Hong Kong Med J 2007;13:216–20.

214. Singh S, Prasad B, Savaliya AA. Strategies for characterizing sildenafil, vardenafil, tadalafil and their analogues in herbal dietary supplements, and detecting counterfeit products containing these drugs. Trends Anal Chem 2009;28:13–28.

215. Vaysse J, Gilard V, Balayssac S, Zedde C, Martino R, Malet-Martino M. Identification of a novel sildenafil analogue in an adulterated herbal supplement. J Pharm Biomed 2012;59:58–66.

216. Lee HM, Kim CS, Jang YM, Kwon SW, Lee BJ. Separation and structural elucidation of a novel analogue of vardenafil included as an adulterant in a dietary supplement by liquid chromatography-electrospray ionization mass spectrometry, infra red spectroscopy and nuclear magnetic resonance spectroscopy. J Pharm Biomed 2011;54:491–6.

217. Chawla R, Thakur P, Chowdhry A, Jaiswal S, Sharma A, Goel R, et al. Evidence based herbal drug standardization approach in coping with challenges of holistic management of diabetes: a dreadful lifestyle disorder of 21st century. J Diabetes Metab Disord 2013;12:35.

218. Diabetes action now—an initiative of the World Health Organisation and International Diabetes Federation; 2004:20.

219. Silva Juinior JOC, Costa RMR, Teixeira FM, Barbosa WLR. Processing and quality control of herbal drugs and their derivatives. In: Shoyama Y, editor. Quality control of herbal medicines and related areas. 2011:195–222.

220. Yongyu Z, Shujun S, Jianye D, Wenyu W, Huijuan C, Jianbing W. Quality control method for herbal medicine. Chem Fingerprint Anal 2011;16:171–94.

221. Singh SK, Chaudhary A, Rai DK, Rai SK. Preparation and characterization of a mercury based Indian traditional drug – Rassindoot. Int J Tradit Knowl 2009;8:346–51.

222. Svcekova M, Havranek E, Novak V. Determination of heavy metals in samples of herbal drugs using differential pulse polarography. J Pharm Biol 1993;42:68–70.

223. Ip SH, Zhao M, Yuan Y, Chen M, Zong Y, Tjong YW. Quality assurance for Chinese herbal formulae: standardization of IBS-20, a 20-herb preparation. J Chin Med 2010;5:1–10.

224. Shen AQ, Morgan L, Barroso ML, Zhang X. Tandem method development of LC–MS analysis of aminoglycoside drugs: challenges and solutions. Answ Pharm Questions Discip Ingenuity 2010;5:567–9.

225. Di X, Kelvin KCC, Leung HW, Carmen WH. Fingerprint profiling of acid hydrolyzates of polysaccharides extracted from the fruiting bodies and spores of Lingzhi by high-performance thin-layer chromatography. J Chromatogr A 2003;1018:85–95.